• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Risk of liver cancer is low in patients with cirrhosis

Bioengineer by Bioengineer
February 1, 2017
in Science News
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Although one of the most serious complications of cirrhosis is liver cancer, or hepatocellular carcinoma (HCC), an analysis of health records revealed that the 10-year incidence of HCC in UK patients with cirrhosis is four percent or lower.

Only 1.2 percent of patients with alcoholic cirrhosis and 1.1 percent of patients with cirrhosis of unknown cause will develop HCC within a decade. The highest 10-year cumulative incidence of HCC was among those with cirrhosis due to chronic viral hepatitis.

"This very low incidence of HCC occurrence in people with cirrhosis caused by alcohol or of unknown origin suggests that surveillance for HCC among these groups is likely to benefit patients little," said Prof. Joe West, lead author of the Alimentary Pharmacology & Therapeutics study. "As surveillance incurs substantial cost, it is therefore unlikely to represent value for money for the NHS. There may well be other ways of spending this money that would benefit patients far more."

###

Media Contact

Penny Smith
[email protected]

http://www.wiley.com/wiley-blackwell

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Exploring NAD+ Precursors for Cognitive Disease Treatment

September 3, 2025

Targeting Cathepsin S Enhances IL-7 Anti-Tumor Immunity

September 3, 2025

Clinician Concerns: Navigating Opioid Management eConsults

September 3, 2025

Prototyping: Enhancing Understanding and Engagement Early

September 3, 2025
Please login to join discussion

POPULAR NEWS

  • Needlestick Injury Rates in Nurses and Students in Pakistan

    296 shares
    Share 118 Tweet 74
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    118 shares
    Share 47 Tweet 30

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring NAD+ Precursors for Cognitive Disease Treatment

Targeting Cathepsin S Enhances IL-7 Anti-Tumor Immunity

Clinician Concerns: Navigating Opioid Management eConsults

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.